COMMUNIQUÉS West-GlobeNewswire

EyePoint Pharmaceuticals to Present at Upcoming Medical Conferences
16/04/2019
Two Presentations Highlighting YUTIQ™ to be Presented at the 2019 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting Data from Two Phase 3 Studies of DEXYCU ™ to be presented at the 2019 American [...]
CureVac Granted Patent Claiming the Combination of mRNA Vaccines with Anti-PD-L1 Antibodies
16/04/2019
PD-L1 Pathway Now Covered as New Patent Complements the mRNA/Anti-PD-1 Antibodies Combination Patent Granted in July 2017 TÜBINGEN, Germany and BOSTON, April 16, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated [...]
Cancer Genetics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Strategic Business Updates
16/04/2019
RUTHERFORD, N.J., April 16, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through diagnostics, molecular markers and data [...]
Axovant Announces Upcoming Presentations at the Annual Meeting of the American Society of Gene and Cell Therapy
16/04/2019
-Details from ongoing SUNRISE-PD Phase 2 trial of AXO-Lenti-PD and the AXO-AAV-GM2 program to be featured in oral presentations- -Preclinical data from AXO-AAV-GM1 program to be highlighted in poster presentation- BASEL [...]
CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Beta Thalassemia
16/04/2019
ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, April 16, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug [...]
IRADIMED CORPORATION to Hold 2019 First Quarter Financial Results Conference Call on April 30th
16/04/2019
WINTER SPRINGS, Fla., April 16, 2019 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2019 first quarter financial results before the market opens on Tuesday, [...]
Recro Pharma Announces Six-Year Extension of License and Supply Agreement Between Teva and Recro Gainesville
16/04/2019
Company Continues Important, Strategic Relationship with Key Global Customer; Long-Term Contract Executed Teva to Continue to be Exclusive Marketing Partner of Verapamil SR ® Capsules with Same Revenue Economics as the [...]
Taconic Biosciences lance TruBIOME ™ en vue de créer des modèles animaux avec des profils de microbiome personnalisés
16/04/2019
RENSSELAER, N.Y., 16 avr. 2019 (GLOBE NEWSWIRE) -- Taconic Biosciences, leader mondial des solutions de modèles de rongeurs génétiquement modifiés, annonce le lancement de TruBIOME TM , une solution unique en son genre [...]
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2019
16/04/2019
Company Announcement Net sales of DARZALEX in the first quarter of 2019 totaled USD 629 million Genmab will receive royalties on worldwide sales from Janssen Biotech, Inc. Copenhagen, Denmark; April 16, 2019 – Genmab A/ [...]
Emergent BioSolutions Announces Interim Results From Phase 2 Study Evaluating CHIKV-VLP, Chikungunya Virus Vaccine Candidate
16/04/2019
GAITHERSBURG, Md., April 16, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced results from the interim analysis of its Phase 2 clinical study evaluating the safety and immunogenicity of the [...]
FDA Agrees to Rolling Review of Mesoblast’s Biologics License Application for Its Cell Therapy in Children With Steroid-Refractory Acute Graft Versus Host Disease
16/04/2019
NEW YORK and MELBOURNE, Australia, April 16, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) global leader in cellular medicines for inflammatory diseases, announced today that the United States Food [...]
ContraFect Presents Additional Positive Data from the Phase 2 Trial of Exebacase at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
16/04/2019
New data include secondary endpoint analyses of clinical responder rates at Day 7, End of Treatment, and Test of Cure, and pre-specified analyses of the clinical responder rates by final diagnosis at Day 14 New MRSA [...]
Corrections to the Latvian version of the news about 3 month results - corrections made only in the list of countries in the table: Unconsolidated sales – March and 3 months
16/04/2019
Corrections have been made only to the Latvian version of the news. Corrections made only in the list of the countries, mentioned in the tables: Unconsolidated sales - March and 3 months. The textual information didn't [...]
Invitation to Q1 conference call
16/04/2019
Oslo, Norway, 16 April 2019 Vistin Pharma ASA will release its first quarter 2019 results on Thursday 25 April 2019. Vistin Pharma will host a conference call for all shareholders and interested parties on 25 April at [...]
Olainfarm appoints new contact for investor relations – Jānis Dubrovskis
16/04/2019
JSC Olainfarm hereby informs that from now on, Investor Relations Advisor Jānis Dubrovskis will be the core contact person for shareholders and investors. The contact details of Jānis Dubrovskis are the following: [...]
SPINEWAY : Souscription de 150 OCEANE
16/04/2019
Communiqué de presse, Ecully le 16 avril 2019. Souscription d’une tranche de 150 obligations convertibles ou échangeables en actions nouvelles et/ou existantes (OCEANE) assorties de bons de souscription d’actions pour [...]
Olainfarm Group sales increase by 14% in Q1 2019
16/04/2019
Consolidated sales – March and 3 months Preliminary consolidated results of JSC Olainfarm for March 2019, show that the Group has made sales worth 10.8 million euros, which represents an increase by 3% compared to March [...]
C-RAD meddelar att teckningsoptioner har utnyttjats och att tilldelning av aktier skett
16/04/2019
C-RAD AB (publ) ("C-RAD" eller "Bolaget") meddelar att 264 000 teckningsoptioner som emitterades efter beslut av årsstämman den 14 april 2016 har utnyttjats av innehavare till en kurs om 11,80 kronor och att styrelsen [...]
Motif Bio Presents New Iclaprim Data at ECCMID 2019
16/04/2019
NEW YORK, April 16, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that new iclaprim data are being [...]

Pages